Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, William G. Wierda et al.|New England Journal of Medicine|2015Cited by 890
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Peter Hillmen et al.|Journal of Clinical Oncology|2021Cited by 630
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory MyelofibrosisJohn Mascarenhas, Maciej Kaźmierczak, Viola Maria Popov et al.|Blood|2024Cited by 15